MEDICINES Australia (MA) has announced a new board and officeholders, after the organisation hosted its annual general meeting in Sydney yesterday.
Boehringer Ingelheim Australia md Wes Cook has been re-elected as Medicines Australia chair, while Dr Anna Lavelle was re-endorsed as Independent Deputy Chair.
Other directors include GSK Australia vice president/gm Anne Belcher; Brad Edwards, gm of Shire Australia; Michala Fischer-Hansen, gm Oceania for Novo Nordisk; Janssen-Cilag md Bruce Goodwin; Takeda Pharmaceuticals Australia md James Jones; Pfizer Australia md Melissa McGregor; Kirsten O'Doherty, gm of AbbVie; Svend Petersen, md of Roche Products; and Bristol-Myers-Squibb Australia md Brent Pfeiffenberger.
MA ceo Milton Catelin congratulated all new and returning board members, who were selected by their peers through a recently conducted members' ballot.
The new Board will serve until Oct 2019, with Catelin also paying tribute to the outgoing directors who "deserve enormous gratitude from the sector for their role in developing a Strategic Agreement with the Commonwealth that provides certainty for industry, incredible value for taxpayers and better access for Australians to innovative medicines".
The above article was sent to subscribers in Pharmacy Daily's issue from 26 Oct 17
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 26 Oct 17